, Cancer Immunotherapy: Whence and Whither. Mol. Cancer Res, vol.15, pp.635-650, 2017.
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4, vol.9, pp.681-692, 2017. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016. ,
DOI : 10.1056/nejmoa1606774
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N. Engl. J. Med, vol.373, pp.23-34, 2015. ,
DOI : 10.1056/nejmoa1504030
URL : https://cronfa.swan.ac.uk/Record/cronfa25005/Download/0025005-20072017114154.pdf
, The Immune Landscape of Cancer. Immunity, vol.48, pp.812-830, 2018.
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Antibodies, vol.5, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02115515
The making of bispecific antibodies, vol.9, pp.182-212, 2017. ,
Naturally occurring antibodies devoid of light chains, Nature, vol.363, pp.446-448, 1993. ,
DOI : 10.1038/363446a0
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold, J. Biol. Chem, vol.284, pp.3273-3284, 2009. ,
, First Global Approval. Drugs, vol.78, pp.1639-1642, 2018.
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies, Proc. Natl. Acad. Sci, vol.103, pp.4586-4591, 2006. ,
Analysis of nanobody paratopes reveals greater diversity than classical antibodies, Protein Eng. Des. Sel, vol.31, pp.267-275, 2018. ,
The immune synapse clears and excludes molecules above a size threshold, Nat. Commun, vol.5, 2014. ,
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody®ALX-0061 supports its clinical development in rheumatoid arthritis, Arthritis Res. Ther, vol.17, 2015. ,
Cancer immunoediting and resistance to T cell-based immunotherapy, Nat. Rev. Clin. Oncol, 2018. ,
Bispecific T-cell engagers for cancer immunotherapy, Immunol. Cell Biol, vol.93, pp.290-296, 2015. ,
DOI : 10.1038/icb.2014.93
URL : http://europepmc.org/articles/pmc4445461?pdf=render
HER2 in solid tumors: More than 10 years under the microscope; where are we now?, Future Oncol, vol.10, pp.1469-1486, 2014. ,
A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity, Oncol. Lett, vol.16, pp.1259-1266, 2018. ,
DOI : 10.3892/ol.2018.8698
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019972
Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization, Protein Eng. Des. Sel, vol.9, pp.617-621, 1996. ,
, Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells, vol.10, pp.780-785, 2017.
DOI : 10.1016/j.tranon.2017.07.003
URL : https://doi.org/10.1016/j.tranon.2017.07.003
The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues, Semin. Cancer Biol, vol.9, pp.67-81, 1999. ,
A novel bispecific antibody, S-Fab, induces potent cancer cell killing, J. Immunother, vol.38, pp.350-356, 2015. ,
DOI : 10.1097/cji.0000000000000099
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy, Int. J. Nanomed, vol.13, pp.3189-3201, 2018. ,
DOI : 10.2147/ijn.s164542
URL : https://www.dovepress.com/getfile.php?fileID=42369
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies, Cancer Immunol. Immunother, vol.67, pp.1251-1260, 2018. ,
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy ,
DOI : 10.1080/2162402x.2017.1377874
URL : http://europepmc.org/articles/pmc5739562?pdf=render
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity, Nat. Commun, vol.9, 2018. ,
DOI : 10.1038/s41467-018-07195-w
URL : https://www.nature.com/articles/s41467-018-07195-w.pdf
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice, Cancer Res, vol.64, pp.378-385, 2004. ,
IL-33-expanded human V?9V?2 T cells have anti-lymphoma effect in a mouse tumor model, Eur. J. Immunol, vol.47, pp.2137-2141, 2017. ,
Adoptively-transferred ex vivo expanded ??-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer, Breast Cancer Res. Treat, vol.122, pp.135-144, 2010. ,
Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local, Front. Immunol, vol.9, p.1305, 2018. ,
Highly specific and potently activating V?9V?2-T cell specific nanobodies for diagnostic and therapeutic applications, Clin. Immunol, vol.169, pp.128-138, 2016. ,
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V?9V?2-T cells ,
, cell immunotherapy for human cancer. Science, vol.359, pp.1361-1365, 2018.
Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase, Exp. Cell Res, vol.317, pp.2630-2641, 2011. ,
DOI : 10.1016/j.yexcr.2011.08.015
A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells, Int. J. Hematol, vol.95, pp.434-444, 2012. ,
Switching CAR T cells on and off: A novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J, vol.6, 2016. ,
A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform, vol.6, 2017. ,
From mono-to bivalent: Improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo, Oncotarget, vol.9, pp.25597-25616, 2018. ,
Nanobody Based Dual Specific CARs, Int. J. Mol. Sci, vol.19, p.403, 2018. ,
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy, Biochim. Biophys. Acta, vol.1840, pp.378-386, 2014. ,
DOI : 10.1016/j.bbagen.2013.09.029
Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma, Proc. Natl. Acad. Sci, vol.114, pp.6623-6631, 2017. ,
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells, Mol. Pharm, vol.15, pp.4577-4588, 2018. ,
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors, Int. Immunopharmacol, vol.62, pp.29-39, 2018. ,
Anti-CTLA-4 therapy requires an Fc domain for efficacy, Proc. Natl. Acad. Sci, vol.115, pp.3912-3917, 2018. ,
Screening and antitumor effect of an anti-CTLA-4 nanobody, Oncol. Rep, vol.39, pp.511-518, 2018. ,
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade ,
Fc?Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis, Cancer Cell, vol.28, pp.285-295, 2015. ,
Preparation and characterization of a novel nanobody against T-cell immunoglobulin ,
, Iran. J. Basic Med. Sci, vol.19, pp.1201-1208, 2016.
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population, Lancet, vol.356, pp.1795-1799, 2000. ,
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors, Cancer Res, vol.73, pp.3499-3510, 2013. ,
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control, Cell, vol.172, pp.1022-1037, 2018. ,
NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses, Blood, vol.113, pp.6593-6602, 2009. ,
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection, Nat. Immunol, vol.3, pp.83-90, 2002. ,
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc?RIIIa gene, Blood, vol.99, pp.754-758, 2002. ,
Trastuzumab-based treatment of HER2-positive breast cancer: An antibodydependent cellular cytotoxicity mechanism?, Br. J. Cancer, vol.94, pp.259-267, 2006. ,
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients, BMC Cancer, vol.10, p.340, 2010. ,
Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism, Blood, vol.118, pp.3347-3349, 2011. ,
Harnessing Fc receptor biology in the design of therapeutic antibodies, Curr. Opin. Immunol, vol.40, pp.78-87, 2016. ,
Fc gamma R-dependent mitogen-activated protein kinase activation in leukocytes: A common signal transduction event necessary for expression of TNF-alpha and early activation genes, J. Exp. Med, vol.184, pp.1027-1035, 1996. ,
Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody ,
Isolation and characterization of anti-Fc?RIII (CD16) llama single-domain antibodies that activate natural killer cells, Protein Eng. Des. Sel, vol.21, pp.1-10, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00258940
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells, PLoS ONE, vol.13, 2018. ,
A novel bispecific antibody, BiSS, with potent anti-cancer activities, Cancer Biol. Ther, vol.17, pp.364-370, 2016. ,
DOI : 10.1080/15384047.2016.1139266
URL : https://www.tandfonline.com/doi/pdf/10.1080/15384047.2016.1139266?needAccess=true
Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc?RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells, Mol. Cancer Ther, vol.12, pp.1481-1491, 2013. ,
DOI : 10.1158/1535-7163.mct-12-1012
URL : https://hal.archives-ouvertes.fr/hal-02115468
A Fc?RIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy, Oncotarget, vol.5, pp.5304-5319, 2014. ,
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity, Cancer Biol. Ther, vol.17, pp.1231-1239, 2016. ,
DOI : 10.1080/15384047.2016.1235659
URL : http://europepmc.org/articles/pmc5199164?pdf=render
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells, vol.6, 2016. ,
DOI : 10.1186/s13568-016-0201-4
URL : https://amb-express.springeropen.com/track/pdf/10.1186/s13568-016-0201-4
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity, J. Immunother, vol.41, pp.1-8, 2018. ,
DOI : 10.1097/cji.0000000000000200
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity, J. Vis. Exp, vol.137, 2018. ,
DOI : 10.3791/57588
A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells, Chembiochem, vol.17, pp.155-158, 2016. ,
DOI : 10.1002/cbic.201500591
URL : http://europepmc.org/articles/pmc5199233?pdf=render
Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment, J. Immunol, pp.422-431, 0200. ,
DOI : 10.4049/jimmunol.1701019
URL : http://www.jimmunol.org/content/jimmunol/200/2/422.full.pdf
The role of myeloid cells in cancer therapies, Nat. Rev. Cancer, vol.16, pp.447-462, 2016. ,
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity, Trends Cancer, vol.4, pp.784-792, 2018. ,
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells, Cell, vol.138, pp.286-299, 2009. ,
DOI : 10.1016/j.cell.2009.05.045
URL : https://doi.org/10.1016/j.cell.2009.05.045
Durable antitumor responses to CD47 blockade require adaptive immune stimulation, Proc. Natl. Acad. Sci, vol.113, pp.2646-2654, 2016. ,
DOI : 10.1073/pnas.1604268113
URL : http://www.pnas.org/content/113/19/E2646.full.pdf
Localized CD47 blockade enhances immunotherapy for murine melanoma, Proc. Natl. Acad. Sci, vol.114, pp.10184-10189, 2017. ,
DOI : 10.1073/pnas.1710776114
URL : https://www.pnas.org/content/pnas/114/38/10184.full.pdf
A Systemic Review of Clinical Trials on Dendritic-Cells Based Vaccine Against Malignant Glioma, J. Carcinog. Mutagen, vol.6, 2015. ,
Trial watch: Dendritic cell-based anticancer immunotherapy, vol.6, 2017. ,
DOI : 10.1080/2162402x.2017.1328341
URL : http://europepmc.org/articles/pmc5543823?pdf=render
Generation of Immunity against Pathogens via Single-Domain Antibody-Antigen Constructs, J. Immunol, vol.197, pp.4838-4847, 2016. ,
DOI : 10.4049/jimmunol.1600692
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806123
Targeted antigen delivery by an anti-class II MHC VHH elicits focused ?MUC1(Tn) immunity ?Electronic supplementary information (ESI) available, Chem. Sci, vol.8, pp.5591-5597, 2017. ,
Targeted Delivery of Cyclotides via Conjugation to a Nanobody, ACS Chem. Biol, vol.13, pp.2973-2980, 2018. ,
Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer, Theranostics, vol.5, pp.597-608, 2015. ,
Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis, Int. J. Mol. Sci, vol.17, 2016. ,
Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation, Bioconjug. Chem, vol.29, pp.2394-2405, 2018. ,
Structurally Defined ?MHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma, Angew. Chem. Int. Ed, vol.55, pp.2416-2420, 2016. ,
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis, Cell Rep, vol.15, 2000. ,
Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway, Acta Pharmacol. Sin, vol.38, pp.1501-1511, 2017. ,
Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress, Cancer Lett, vol.356, pp.946-952, 2015. ,
Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery, Small, vol.14, p.1802372, 2018. ,
The Regulatory Role of Invariant NKT Cells in Tumor Immunity, Cancer Immunol. Res, vol.3, pp.425-435, 2015. ,
Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features, Immunology, vol.149, pp.111-121, 2016. ,
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells, Gene Ther, vol.19, pp.1133-1140, 2012. ,
Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: Implications for in vivo targeted vaccine delivery, Gene Ther, vol.24, pp.370-375, 2017. ,
Tumor necrosis factor and cancer, buddies or foes?, Acta Pharmacol. Sin, vol.29, pp.1275-1288, 2008. ,
TNF signaling drives myeloid-derived suppressor cell accumulation, J. Clin. Investig, vol.122, pp.4094-4104, 2012. ,
Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2 ,
TNF? blockade overcomes resistance to anti-PD-1 in experimental melanoma, Nat. Commun, 2017. ,
Neutralization of TNF? in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer, Cancer Lett, vol.386, pp.24-34, 2017. ,
Identification and in vitro characterization of novel nanobodies against human granulocyte colony-stimulating factor receptor to provide inhibition of G-CSF function, Biomed. Pharmacother, vol.93, pp.245-254, 2017. ,
Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival, Med. Sci. Monit, vol.24, pp.1701-1711, 2018. ,
are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration, Br. J. Cancer, vol.110, pp.1211-1220, 2014. ,
G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation, Cancer Res, vol.75, pp.2566-2579, 2015. ,
An underappreciated yet critical hurdle for successful cancer immunotherapy, vol.97, pp.669-697, 2017. ,
The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review), Int. J. Mol. Med, vol.32, pp.1239-1246, 2013. ,
The CXL12/CXCR4/CXCR7 axis in female reproductive tract disease: Review, Am. J. Reprod. Immunol, vol.80, 2018. ,
CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice, Clin. Exp. Metastasis, vol.31, pp.339-349, 2014. ,
CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver, Oncol. Rep, 2018. ,
Mechta-Grigoriou, F. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients, vol.36, pp.1211-1222, 2017. ,
Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth In Vivo, J. Biol. Chem, vol.288, pp.29562-29572, 2013. ,
CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer, Mol. Carcinog, vol.58, pp.144-155, 2019. ,
CXCL12 (SDF1?)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?, Clin. Cancer Res, vol.17, 2011. ,
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry, Biochem. Pharmacol, vol.158, pp.402-412, 2018. ,
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells, Proc. Natl. Acad. Sci, vol.107, pp.20565-20570, 2010. ,
Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions, Biochem. Pharmacol, vol.158, pp.413-424, 2018. ,
IL-2: The First Effective Immunotherapy for Human Cancer, J. Immunol, vol.192, pp.5451-5458, 2014. ,
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs, Cancer Immunol. Res, vol.6, pp.389-401, 2018. ,
A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. Drug Des, Dev. Ther, vol.12, pp.2645-2654, 2018. ,
Converting IL-15 to a superagonist by binding to soluble IL-15R?, Proc. Natl. Acad. Sci, vol.103, pp.9166-9171, 2006. ,
Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer, Immunobiology, vol.217, pp.1266-1272, 2012. ,
Nanobody immunostaining for correlated light and electron microscopy with preservation of ultrastructure, Nat. Methods, vol.15, pp.1029-1032, 2018. ,
Site-specific protein modification using immobilized sortase in batch and continuous-flow systems, Nat. Protoc, vol.10, pp.508-516, 2015. ,
Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: A versatile strategy for multiple molecular imaging modalities, Contrast Media Mol. Imaging, vol.11, pp.328-339, 2016. ,
Site-Specific Labeling of His-Tagged Nanobodies with 99mTc: A Practical Guide, Single Domain Antibodies: Methods and Protocols ,
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers, Oncotarget, vol.8, pp.41932-41946, 2017. ,
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma, J. Nucl. Med, vol.57, pp.27-33, 2016. ,
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma, Mol. Cancer Ther, vol.16, pp.2828-2839, 2017. ,
A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells ,
Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging, J. Nucl. Med, vol.58, pp.1210-1215, 2017. ,
In vivo near-infrared fluorescence targeting of T cells: Comparison of nanobodies and conventional monoclonal antibodies, Contrast Media Mol. Imaging, vol.9, pp.135-142, 2014. ,
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells, J. Exp. Med, vol.214, pp.2243-2255, 2017. ,
Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages, Cancer Res, vol.72, pp.4165-4177, 2012. ,
Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments, J. Nucl. Med, vol.56, pp.1265-1271, 2015. ,
Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease, J. Nucl. Med, vol.58, pp.1003-1008, 2017. ,
Use of 18F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer, ACS Cent. Sci, vol.1, pp.142-147, 2015. ,